Compositions and Methods of Sphingosine Kinase Inhibitors In Radiation Therapy of Various Cancers

Abstract

The present invention relates to Sphingosine kinase inhibitors that are useful for treating various cancers. The invention further relates to compositions and methods of SPK inhibitors, including siRNAs, which specifically block gene expression of SPK and potentiates the effect of radiation in the treatment of various cancers.

1 - 22 . (canceled) 
     
     
         23 . A method of treating cancer in a subject, comprising:
 administering to cancer cells in said subject a siRNA inhibitor in an amount sufficient to block the expression of sphingosine kinase 1 (SPK1) in the cancer cells and potentiate an effect of radiation, wherein the siRNA comprises a sense sequence and an antisense sequence, and the antisense sequence is complementary to an mRNA encoding SPK1, and   administering radiation to the subject in an amount greater than or equal to 100 rads and less than or equal to 500 rads during the time period the effect of the radiation is potentiated by blocking expression of SPK1.   
     
     
         24 . The method of  claim 23 , wherein the siRNA is double stranded and comprises a sense sequence comprising SEQ ID NO: 1 and an antisense sequence comprising SEQ ID NO: 2. 
     
     
         25 . The method of  claim 23 , wherein the siRNA is double stranded and comprises a sense sequence comprising SEQ ID NO: 3 and an antisense sequence comprising SEQ ID NO: 4. 
     
     
         26 . The method of  claim 23 , wherein the siRNA comprises 19-25 nucleotides. 
     
     
         27 . The method of  claim 23 , wherein the cancer is breast, prostate, colorectal, lung, bladder, head and neck, intestine, ovarian, or skin cancer. 
     
     
         28 . The method of  claim 23 , wherein the siRNA inhibitor is effective at blocking expression and potentiating the effect of radiation in least two or more different kinds of the cancer. 
     
     
         29 . The method of  claim 23 , wherein the subject is a mammal. 
     
     
         30 . The method of  claim 23 , further comprising periodically re-administering the radiation. 
     
     
         31 . The method of  claim 30 , where the radiation is periodically administered at a rate of at least twice per week. 
     
     
         32 . The method of  claim 30 , wherein the cancer is head and_neck cancer. 
     
     
         33 . A method of treating head and/or neck cancer in a subject, comprising:
 administering to head and/or neck cancer cells in the subject a siRNA inhibitor in an amount sufficient to block the expression of sphingosine kinase 1 (SPK1) in the cancer cells and potentiate an effect of radiation, wherein the siRNA comprises a sense sequence and an antisense sequence, and the antisense sequence is complimentary to an mRNA encoding SPK1, and   administering radiation to the subject in an amount greater than or equal to 100 rads and less than or equal to 500 rads at a time when the effect of the radiation is potentiated by blocking expression of SPK1.   
     
     
         34 . The method of  claim 33 , wherein the siRNA is double stranded and comprises a sense sequence comprising SEQ ID NO: 1 and an antisense sequence comprising SEQ ID NO: 2. 
     
     
         35 . The method of  claim 33 , wherein the siRNA is double stranded and comprises a sense sequence comprising SEQ ID NO: 3 and an antisense sequence comprising SEQ ID NO: 4. 
     
     
         36 . The method of  claim 33 , wherein the siRNA comprises 19-25 nucleotides. 
     
     
         37 . The method of  claim 33 , further comprising periodically re-administering the radiation. 
     
     
         38 . The method of  claim 37 , where the radiation is periodically administered at a rate of at least twice per week. 
     
     
         39 . A method of treating cancer in a subject, comprising:
 administering to cancer cells in said subject a siRNA inhibitor in an amount sufficient to block the expression of sphingosine kinase 1 (SPK1) in the cancer cells and potentiate an effect of radiation, wherein the siRNA comprises a sense sequence and an antisense sequence, and the antisense sequence is complementary to an mRNA encoding SPK1, and   administering radiation to the subject in an amount greater than or equal to 100 rads and less than or equal to 500 rads.   
     
     
         40 . A method of treating cancer in a subject, comprising:
 administering to cancer cells in said subject a siRNA inhibitor in an amount sufficient to block the expression of sphingosine kinase 1 (SPK1) in the cancer cells and potentiate an effect of radiation, wherein the siRNA comprises a sense sequence and an antisense sequence, and the antisense sequence is complementary to an mRNA encoding SPK1, and   administering radiation to the subject.